CNS vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
CNS exhibits a stable financial foundation with a Piotroski F-Score of 5/9 and very low debt (D/E 0.22), but it is fundamentally overvalued. The current price of $67.71 trades at a significant premium to both the Graham Number ($27.35) and the growth-based Intrinsic Value ($50.59). This valuation gap is compounded by a bearish technical trend (0/100), insider selling, and a dangerously high dividend payout ratio of 83.77%. Recent earnings performance is lackluster, with only one beat in the last four quarters.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
CNS vs JPM: Head-to-Head Comparison
This page compares Cohen & Steers, Inc. (CNS) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.